Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Repetitive transcranial magnetic stimulation-induced severe hypotension in a patient with Parkinson's disease: a case report.

Acta neurologica Belgica·2026
Same author

Repetitive transcranial magnetic stimulation-induced severe hypotension in a patient with Parkinson's disease: a case report.

Acta neurologica Belgica·2026
Same author

Anti-myeloperoxidase-ANCA-associated vasculitis presenting with sudden sensorineural hearing loss: a case report.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Deep-learning analysis of speech using mel-spectrograms for the assessment of mild cognitive impairment and Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2025
Same author

White Matter Hyperintensities in Relation to Cognition and Amyloid Burden in a South Korean Cohort With Subjective Cognitive Decline.

Alzheimer disease and associated disorders·2025
Same author

The Effects of Transcranial Direct Current Stimulation on Acute Ischemic Stroke-A Randomized, Double-blind, Sham-Controlled Study.

The neurologist·2025

Related Experiment Video

Updated: Jun 5, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Cognitive dysfunction in drug induced parkinsonism (DIP).

Young-Do Kim1, Joong-Seok Kim, Sung-Woo Chung

  • 1Department of Neurology, The Catholic University of Korea, Seoul St Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.

Archives of Gerontology and Geriatrics
|December 18, 2010
PubMed
Summary

Cognitive impairment in drug-induced parkinsonism (DIP) is common and similar to Parkinson's disease (PD). Cognitive deficits in DIP may be toxic/metabolic or a risk factor, with outcomes varying after drug withdrawal.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Area of Science:

  • Neurology
  • Neuropsychology

Background:

  • Dementia is a known risk factor for drug-induced parkinsonism (DIP).
  • Limited research exists on the cognitive characteristics and prognosis of DIP.

Purpose of the Study:

  • To investigate cognitive impairments in DIP.
  • To compare cognitive status in DIP patients with Parkinson's disease (PD) and normal controls.
  • To assess the longitudinal cognitive outcomes in DIP after drug withdrawal.

Main Methods:

  • Neuropsychological testing and brain MRI were performed on 13 DIP patients and 91 PD patients.
  • DIP patients were followed for over six months post-drug withdrawal.
  • Cognitive function was compared between DIP patients, PD patients, and controls.

Main Results:

  • DIP patients exhibited significantly worse cognitive function than controls across most domains.
  • No significant cognitive differences were observed between DIP and PD patients.
  • Motor impairment severity correlated with cognitive function in DIP patients.
  • Cognitive impairment in DIP was sometimes transient and reversible, but often persistent or worsening after drug discontinuation.

Conclusions:

  • Cognitive impairment in DIP is associated with toxic/metabolic effects of the offending drug.
  • Cognitive deficits in DIP may reflect an increased risk for developing the condition.
  • The variable cognitive prognosis in DIP highlights the need for careful monitoring and management.